Clinuvel Pharmaceuticals (ASX:CUV) Price-to-Tangible-Book : 4.09 (As of Apr. 28, 2024)

View and export this data going back to 2001. Start your Free Trial

What is Clinuvel Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-04-28), Clinuvel Pharmaceuticals's share price is A$14.57. Clinuvel Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was A$3.56. Hence, Clinuvel Pharmaceuticals's Price to Tangible Book Ratio of today is 4.09.

The historical rank and industry rank for Clinuvel Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

ASX:CUV' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.09 Med: 13.43 Max: 28.93
Current: 4.09

During the past 13 years, Clinuvel Pharmaceuticals's highest Price to Tangible Book Ratio was 28.93. The lowest was 4.09. And the median was 13.43.

ASX:CUV's Price-to-Tangible-Book is ranked worse than
66.31% of 1220 companies
in the Biotechnology industry
Industry Median: 2.65 vs ASX:CUV: 4.09

A closely related ratio is called PB Ratio. As of today, Clinuvel Pharmaceuticals's share price is A$14.57. Clinuvel Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was A$3.56. Hence, Clinuvel Pharmaceuticals's P/B Ratio of today is 4.09.

Clinuvel Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Price-to-Tangible-Book Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Price-to-Tangible-Book

Get a 7-Day Free Trial

28.93

17.25

15.39

5.85

5.37

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															12.55	5.85	7.70	5.37	4.49

Competitive Comparison of Clinuvel Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Price-to-Tangible-Book falls into.

Clinuvel Pharmaceuticals Price-to-Tangible-Book Calculation

Clinuvel Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	14.57	/	3.56
	=	4.09

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Clinuvel Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (ASX:CUV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (ASX:CUV) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

CLVLY:USA CLVLF:USA UR9:Germany

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (ASX:CUV) Headlines

No Headlines